Medicare Add-On Payments For Praxbind, Andexanet Under Consideration
This article was originally published in The Pink Sheet Daily
Executive Summary
Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.
You may also be interested in...
Six Weeks Too Late? Praxbind Gets 2017 Medicare Boost But Not AndexXa
User fee date for Portola's anticoagulant reversal agent is near, but not soon enough for Medicare's new technology payments in 2017 – while Boehringer's Praxbind gets in in time; BTG's Vistogard also gains the extra payments.
Medical Benefit, Hospital Drugs Exempt From Detailed Cost, Coverage Reporting In Final Rule
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.
Pfizer Getting $529 Per Course For Paxlovid Under US Contract; Did Merck Drive A Harder Bargain?
US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.